Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Zipp

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Der Nervenarzt|June 9, 2018
[New aspects of immunotherapy in multiple sclerosis]K Pape, F Zipp, S Bittner
Ernst Schering Research Foundation Workshop|June 18, 2002
The role of apoptosis in neuroinflammationF Zipp, O Aktas, J D Lünemann
Journal of Neural Transmission. Parkinson'S Disease and Dementia Section|January 1, 1993
Lamotrigine--antiparkinsonian activity by blockade of glutamate release?F Zipp, H Baas, P A Fischer
Immunology Today|November 24, 1999
Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand systemF Zipp, P H Krammer, M Weller
Nature Medicine|September 2, 1999
No increase in demyelinating diseases after hepatitis B vaccinationF Zipp, J G Weil, K M Einhäupl
Brain Research|August 21, 1989
Entorhinal fibers form synaptic contacts on parvalbumin-immunoreactive neurons in the rat fascia dentataF Zipp, R Nitsch, E Soriano, et al.
Der Nervenarzt|November 18, 2000
[Apoptosis in multiple sclerosis. Etiopathogenetic relevance and prospects for new therapeutic strategies]O Aktas, U Wendling, R Zschenderlein, et al.
Journal of Neuro-Oncology|March 5, 1999
Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?J R Streffer, M Schuster, F Zipp, et al.
Journal of Molecular Medicine (Berlin, Germany)|January 16, 2008
New developments in understanding and treating neuroinflammationC Infante-Duarte, S Waiczies, J Wuerfel, et al.
Acta Neurologica Scandinavica|June 5, 1998
Glutamine synthetase activity in patients with Parkinson's diseaseF Zipp, L Demisch, A Derouiche, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Der Nervenarzt|June 9, 2018
[New aspects of immunotherapy in multiple sclerosis]K Pape, F Zipp, S Bittner
Ernst Schering Research Foundation Workshop|June 18, 2002
The role of apoptosis in neuroinflammationF Zipp, O Aktas, J D Lünemann
Journal of Neural Transmission. Parkinson'S Disease and Dementia Section|January 1, 1993
Lamotrigine--antiparkinsonian activity by blockade of glutamate release?F Zipp, H Baas, P A Fischer
Immunology Today|November 24, 1999
Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand systemF Zipp, P H Krammer, M Weller
Nature Medicine|September 2, 1999
No increase in demyelinating diseases after hepatitis B vaccinationF Zipp, J G Weil, K M Einhäupl
Brain Research|August 21, 1989
Entorhinal fibers form synaptic contacts on parvalbumin-immunoreactive neurons in the rat fascia dentataF Zipp, R Nitsch, E Soriano, et al.
Der Nervenarzt|November 18, 2000
[Apoptosis in multiple sclerosis. Etiopathogenetic relevance and prospects for new therapeutic strategies]O Aktas, U Wendling, R Zschenderlein, et al.
Journal of Neuro-Oncology|March 5, 1999
Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?J R Streffer, M Schuster, F Zipp, et al.
Journal of Molecular Medicine (Berlin, Germany)|January 16, 2008
New developments in understanding and treating neuroinflammationC Infante-Duarte, S Waiczies, J Wuerfel, et al.
Acta Neurologica Scandinavica|June 5, 1998
Glutamine synthetase activity in patients with Parkinson's diseaseF Zipp, L Demisch, A Derouiche, et al.
Pageof 9